DULLES, Va., Oct. 13, 2022 /PRNewswire/ -- SOFIE Biosciences (SOFIE), an established US manufacturer and developer of radiopharmaceuticals, has dosed and imaged the first patient with [68 Ga]FAPI-46 ...
Figure 1. Male, 46 years old, with IIP for 1 month, manifests FDG and FAPI imaging positive. (A, E, the MIP of FDG and FAPI imaging; B-C, axial FDG PET/CT, CT, and the FAPI PET/CT; The SUVmax of the ...
FAPI PET/CT may be the better imaging tool to predict renal response to lupus nephritis induction therapy. For noninvasively predicting renal response to lupus nephritis induction therapy, the ...
Figure 1. Clinical stage changed by FAPI PET/CT categorized by 18 F-FDG PET/CT in newly diagnosed breast cancer. Toronto, Ontario—A comparative analysis between FAPI and 18 F-FDG PET/CT for the ...
DULLES, Va., Oct. 1, 2025 /PRNewswire/ -- SOFIE Biosciences, an established U.S. manufacturer and developer of radiopharmaceuticals, today announced the successful completion of an end-of-phase 2 ...
DULLES, Va., Feb. 11, 2026 /PRNewswire/ -- SOFIE Biosciences, an established U.S. manufacturer and developer of radiopharmaceuticals, today announced that the first patient has been dosed in the ...
PET imaging with 68 Ga-FAPI can more effectively detect and stage pancreatic cancer as compared with 18 F-FDG imaging or contrast-enhanced CT, according to new research published in the December issue ...
Improving differential diagnosis of pulmonary large cell neuroendocrine carcinoma (LCNEC) and small cell lung cancer via a transcriptomic, biological pathway-based ridge regression model. This is an ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results